# Phase II Randomized Trial of Radiation Therapy in Oligometastatic mCRPC Prostate Cancer (ARTO)

> **NCT03449719** · NA · UNKNOWN · sponsor: **Lorenzo Livi** · enrollment: 174 (estimated)

## Conditions studied

- Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone

## Interventions

- **RADIATION:** SBRT - Ablative radiation Therapy
- **DRUG:** Abiraterone Acetate

## Key facts

- **NCT ID:** NCT03449719
- **Lead sponsor:** Lorenzo Livi
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-01
- **Primary completion:** 2021-09-01
- **Final completion:** 2022-05-01
- **Target enrollment:** 174 (ESTIMATED)
- **Last updated:** 2018-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03449719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03449719, "Phase II Randomized Trial of Radiation Therapy in Oligometastatic mCRPC Prostate Cancer (ARTO)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03449719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*